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Four distinct transmembranous glycoprotein receptors have been
identified as members of the Type 1 growth factor receptor family,
a class of oncogenes prevalent in several solid tumours, especially
those of the breast (reviewed in Mason and Gullick, 1995). They
are the epidermal growth factor receptor (EGFR), c-erbB-2, 
c-erbB-3 and c-erbB-4 (alternatively, authors may use the HER
terminology instead, e.g. HER1 etc). Receptor heterodimerization
(Earp et al, 1995), a unique feature of the Type 1 receptors, enables
multifunctional intracellular responses to be generated with
differing strengths and specificities dependent on the ligand type,
specific receptor combination or relative level of receptor expres-
sion. Previous studies have shown that overexpression of EGFR,
c-erbB-2 and c-erbB-3 is associated with worse disease prognosis
in breast cancer (Slamon et al, 1987; Lewis et al, 1990, 1996;
Lovekin et al, 1991; Klijn et al, 1992; Lemoine et al, 1992; Travis
et al, 1996). The most common causes of Type 1 receptor over-
expression are gene amplification and/or an increased gene trans-
cription rate. Much interest has been generated recently by the
possibility of utilizing the Type 1 receptors as prognostic indica-
tors in breast carcinomas and the development of treatments in the
form of kinase inhibitors and monoclonal antibodies (Bridges,
1996).
The most recently identified member of this family, c-erbB-4,
was cloned in 1993 (Plowman et al, 1993). The c-erbB-4 gene is
localized on chromosome 2q33.3–34 (Zimonjic et al, 1995) and
encodes a protein of 1283 amino acids with a molecular weight of
180 kDa after post-translational glycosylation. Although EGFR, 
c-erbB-2 and c-erbB-3 are all expressed as soluble, truncated
receptors as a result of mRNA splicing, c-erbB-4 exists as two
full-length variants possessing alternative extracellular juxtamem-
brane sequences which are differentially sensitive to proteolysis
(Elenius et al, 1997b). Protein kinase C activators (e.g. 12-O-
tetradecanoylphorbol-13-acetate, platelet-derived growth factor)
have been shown to induce rapid and extensive selective
proteolytic cleavage of the c-erbB-4 receptor molecule, yielding a
membrane-dependent 80-kDa fragment consisting of the entire
cytoplasmic and transmembrane domain, and a soluble 120-kDa
ectodomain fragment which is released into the extracellullar
space (Vecchi et al, 1996; Vecchi and Carpenter, 1997).
Expression of the c-erbB-4 receptor is found in several breast
adenocarcinoma cell lines (e.g. MDA-MB-453, T47-D, BT-474
and H3396), and in a range of normal human fetal and adult tissues
at the mRNA (Plowman et al, 1993a); Srinivasan et al, 1998) and
protein levels (Srinivasan et al, 1998), notably in the brain and
heart. More specifically, c-erbB-4 has also been found expressed
at the post-synaptic membrane of neuromuscular synapses (Zhu 
et al, 1995). The c-erbB-4 receptor is activated by ligands known
as heregulins or neuregulins (Plowman et al, 1993b). These are
encoded by three separate genes, NRG-1 (the human homologue
of the mouse NDF gene) found at chromosome 8p12–21 (Orr-
Urteger et al, 1993), and two more recently described genes NRG-
2 (also known as Don1 and NTAK) (Busfield et al, 1997;
Carraway et al, 1997; Chang et al, 1997; Higashiyama et al, 1997)
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and NRG-3 located on chromosome 10q22 (Zhang et al, 1997).
The first two of these genes are known to produce multiple
proteins possessing different structural domains as a consequence
of mRNA splicing (Wen et al, 1994). In addition, several ligands
originally described as activators of EGFR are now known also to
bind directly to and to stimulate the activity of c-erbB-4. Examples
of these include betacellulin (Riese et al, 1996), heparin-binding
EGF (Elenius et al, 1997a) and epiregulin (Komurasaki et al,
1997).
Consistent with its pattern of expression, knock-out mice
studies have suggested that c-erbB-4 plays an essential role as an
in vivo regulator of both cardiac muscle differentiation and
axonal guidance in the central nervous system (Gassmann et al,
1995; Zhu et al, 1995). Gassman et al reported that mice lacking
c-erbB-4 died during mid-embryogenesis from the aborted devel-
opment of myocardial trabeculae in the heart ventricle. In addi-
tion, alterations of the innervation of the hindbrain were also
reported.
The relationship between c-erbB-4 expression and cancer prog-
nosis is, at present, poorly understood. Srinivasan et al (1998)
found that the immunohistochemical expression of c-erbB-4
tended to be higher in normal tissues than in most of the types of
cancers studied. Similar results have been obtained by Lyne et al
(1997) in prostate cancer and by Baccus et al (1996) breast carci-
noma, the latter also demstrating divergent correlates between 
c-erbB-2 and c-erbB-4 (Baccus et al, 1996). In this study, we
demonstrated the immunohistochemical expression of c-erbB-4 in
breast cancer using the HFR-1 monoclonal antibody. We also
examined for possible correlations between its expression and
various indicators of clinical prognosis, with a view to assessing
the possible value of c-erbB-4 expression as an independent prog-
nostic indicator in breast carcinomas.
MATERIALS AND METHODS
Patients
A consecutive series of 133 patients presenting with primary oper-
able invasive breast carcinoma to a single surgeon (RW Blamey) at
the Nottingham City Hospital between 1975 and 1977 was exam-
ined. The treatment administered involved mastectomy (simple or
subcutaneous) or breast conservation surgery with radiotherapy.
During surgery itself, lymph nodes were sampled by the triple
node biopsy technique (Todd et al, 1987) and the tumour subse-
quently staged. No systemic adjuvant therapy was administered.
Long-term follow-up of patients was maintained after surgery by
regular visits to the clinic. These were conducted at 3-monthly
intervals for 18 months, and then every 6 months for 5 years, and
then annually. Any major tumour recurrence was recorded as
either loco-regional (recurrences requiring some form of major
treatment, e.g. radiotherapy) or distant (confirmed radiologically
by isotope scan or liver function tests). The disease-free interval
was taken as the time (in months) from the date of primary treat-
ment to the first loco-regional or distant recurrence. The overall
survival was defined as the time (in months) from the date of
primary treatment to the time of death.
Of the 133 patients entered into the study, six were removed
because data on certain prognostic variables was not available
from the computer database. This leaves a total of 127 patients. All
patients were aged 70 years or below.
Tissue preparation
The excised tumours were sliced and measured in three perpendic-
ular planes. This was done immediately post-excision to reduce
the possibility of autolytic artifacts. The largest of these three
dimensions constituted the actual tumour size recorded. Fresh
tumour blocks were snap-frozen or fixed in neutral buffered
formalin and then embedded in paraffin wax for receptor assay,
immunochemistry and archival storage. Histological grade (Elston
and Ellis, 1991), tumour type (Ellis et al, 1992), menopausal status
(Todd et al, 1987) and vascular invasion (Pinder et al, 1994) were
recorded for each tumour sample. A Nottingham Prognostic Index
(NPI) score was calculated for each patient based on the following
equation (Haybittle et al, 1982):
I 5 0.2 3 size (in cm) 1 stage 1 grade
Patients were then assigned into the good (I ≤ 3.4), moderate 
(3.4 < I ≤ 5.4) or poor (I > 5.4) prognostic groups according to the
score obtained. In addition, assays to determine the oestrogen
receptor (ER) status of each tumour section were conducted (at the
Tenovus Institute, Cardiff) by the dextran-coated charcoal method.
Tumours were classified ER-positive if they contained more than 
5 femtomoles of specific oestradiol binding per mg of cytosol
protein (Todd et al, 1987). Finally, tumour sections were divided
into four different histological groups with different prognostic
indications (Pereira et al, 1995):
Group 1: Tubular, tubulo-lobular, mucoid and invasive cribri-
form carcinoma.
Group 2: Tubular mixed, mixed ductal with special type, and
alveolar lobular carcinoma.
Group 3: Classical lobular, medullary, atypical medullary and
lobular mixed.
Group 4: Ductal NST, solid lobular, mixed ductal and lobular
carcinoma.
Immunohistochemistry
The tumour samples were then stained immunohistochemically
with the HFR-1 monoclonal antibody using the Duet StreptABC
Method (A = streptavidin, B = biotinylated peroxidase, C =
biotinylated goat anti-mouse/rabbit immunoglobulin) with DAB
as the chromogen and haematoxylin as the counterstain. HFR-1 is
a mouse monoclonal antibody raised against residues 1249–1264
of the c-erbB-4 cytoplasmic domain. It has been shown to
recognize c-erbB-4 by immunoprecipitation, Western blotting and
immunostaining of cytocentrifuge preparations of NIH3T3 cells
transfected with c-erbB-4 (Srinivasan et al, 1998). Initially, the
antibody was supplied at a concentration of 1.5 mg ml–1. After
repeated trials to find a suitable dilution concentration with the
most appropriate balance of protein expression and background
staining, a ratio of 1/700 was decided upon, giving a final antibody
concentration of approximately 2.14 mg ml–1. Sections of normal
breast tissue were used as positive controls, and omission of the
primary antibody and blockade of the primary antibody with
peptide 96.4 were used as negative controls.The final protein expression was classified using a simple semi-
quantitative scoring method, based on three distinct sites of
reactivity. To increase the objectivity and accuracy of the scoring
process, the shade of brown reaction product expressed in the cyto-
plasm was compared to a colour chart available commercially as
the ICI Dulux Colour Palette™. The scoring criteria used are as
follows:
1. Nuclear reactivity
0 = No reactivity
1 = Pale brown and finely granular
2 = Dark opaque brown
2. Cytoplasmic reactivity
0 = Clear cytoplasm
1 = First shade of colour chart
2 = Second shade of colour chart
3 = Third shade of colour chart
3. Membrane accentuation
0 = No membrane accentuation
1 = 0–10% of cells demonstrating membrane accentuation
2 = >10% of cells demonstrating membrane accentuation.
To ensure consistency of scoring, pairs of sections with
similar scores were randomly chosen for re-assessment. The
observed reactivities were compared between the two sections,
and scores were re-adjusted if necessary. Approximately 20
sections were scored blind by two pathologists (IOE and HD)
using the same scoring criteria. Results from Spearman rank
correlation analysis indicated that the inter-observer agreement
was good for cytoplasmic (Rho = 0.647) and membrane (Rho =
0.510) reactivity.
Statistical analysis
The semi-quantitative scores assigned to each patient case 
were entered into a statistical software program which contained
information on a variety of factors recorded routinely (see Table
1). This is the fourth in a series of similarly designed studies inves-
tigating the individual expression of Type 1 receptors in breast
carcinoma patients, enabling us to utilize data on the expression of
EGFR (Lewis et al, 1990), c-erbB-2 (Lovekin et al, 1991) and c-
erbB-3 (Travis et al, 1996) for statistical analyses. Univariate c2
analyses were conducted for each of the sites of reactivity
mentioned and several known prognostic factors in breast cancer.
Survival data were examined using the Kaplan–Meier method and
the log-rank (Mantel–Cox) test. All analyses were carried out
using standard commercial statistical computer software (Stat
View 4.1).
RESULTS
In this study, c-erbB-4 immunoreactivity using HFR-1 antibody
was localized to ductal and lobular units (both normal and malig-
nant) and accompanied by an acceptable level of background
staining. Within malignant cells, immunoreactivity was predomi-
nantly cytoplasmic, although nuclear and membrane reactivity
were also present. The level of c-erbB-4 protein expression in
tumour cell populations was generally low (as such the scoring
process more difficult than initially envisaged), but definite cyto-
plasmic, membrane and nuclear reactivity (score 2 or above) was
identified in 58%, 41% and 25% of cases respectively. Although
statistically significant correlations were demonstrated between
these three sites of expression, careful analysis of the contingency
tables revealed no definite pattern of interaction.
Chi-square tests
Statistically significant associations were demonstrated between
histological grade and c-erbB-4 nuclear (Table 1 and 4; Figure 
4), cytoplasmic (Tables 2 and 5; Figure 5) and membrane expres-
sion (Tables 3 and 6; Figure 6). In contrast to the other Type 1
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Table 1 Results of chi square tests for c-erbB-4 nuclear reactivity
Prognostic factor Cut-off points c2 c2
P-value
Grade 1, 2, or 3 10.781 0.0291a
Lymph node stage 1, 2, or 3 5.888 0.2077
Local recurrence Absent or present 0.048 0.9761
Distant metastases Absent or present 0.245 0.8845
Vascular invasion None or definite 0.135 0.9346
Tumour size ≤ 1.5 or > 1.5 cm 1.174 0.5559
NPI groups Good, moderate, or poor 3.112 0.5393
prognostic group
Histological type 1, 2, 3, 4 or 5 6.814 0.3384
Age < 40, 40–49, 50–59, 60–69 or 5.919 0.6563
> 70 years
Menopausal status Pre- or post-menopausal 2.324 0.3128
ER status Negative or positive 2.486 0.2886
EGFR Negative, mild, moderate or 6.944 0.3260
strong immunoreactivityb
C-erbB-2 Negative or positiveb 1.681 0.4314
C-erbB-3 Negative, mild, moderate or 12.078 0.0602
strong immunoreactivityb
See under Materials and Methods for detailed description of criteria for cut-off points. aFigures
highlighted indicate statistically significant P-values (P < 0.05). bFor further information on
EGFR, c-erbB-2 and c-erbB-3 scoring criteria, refer to Lewis et al (1990), Lovekin et al (1991)
and Travis et al (1996) respectively.1166 TY Kew et al
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receptors (Lewis et al, 1990; Lovekin et al, 1991; Travis et al,
1996), the relationship is an inverse one, i.e. c-erbB-4 expression
tended to favour well differentiated tumours. In addition, c-erbB-
4 membrane accentuation demonstrated an inverse association
with the NPI: fewer tumours expressed c-erbB-4 with worsening
prognostic grouping (Tables 3 and 7; Figure 7). Statistically
significant associations were also seen between c-erbB-4 cyto-
plasmic expression and both c-erbB-3 expression and tumour
stage (Table 2), although no distinct trend was identifiable from
contingency tables (not shown). No correlations were found
between the three sites of immunoreactivity for c-erbB-4 and the
prognostic factors and follow-up events viz. overall survival or
disease-free interval (DFI), local recurrence, distant metastasis,
vascular invasion, tumour size, histological type, age, menopausal
status and ER status.
DISCUSSION
This study has demonstrated that c-erbB-4 protein expression can
be identified in both normal and malignant breast epithelium.
Expression in adenocarcinoma is most frequently cytoplasmic,
with nuclear and membrane localization seen in a small proportion
of cases. Other studies on the immunohistochemical expression of
c-erbB-4 in tumours of the prostate (Lyne et al, 1997), thyroid
(Faksvag Haugen et al, 1996) and in medulloblastoma (Gilbertson
et al, 1997) also demonstrated predominantly cytoplasmic reac-
tivity. Srinivasan et al (1998) however showed occasional nuclear
staining in paraffin-embedded and in frozen sections of some
Table 2 Results of chi square tests for c-erbB-4 cytoplasmic reactivity
Prognostic factor c2 c2 P-value
Grade 13.141 0.0408
Lymph node stage 13.554 0.0350
Local recurrence 0.566 0.9042
Distant metastases 0.662 0.8822
Vascular invasion 1.195 0.7541
Tumour size 4.767 0.1897
NPI groups 6.567 0.3628
Histological type 9.456 0.3963
Age 16.303 0.1778
Menopausal status 1.906 0.5922
ER status 1.132 0.7694
EGFR 15.012 0.0906
C-erbB-2 2.514 0.4727
C-erbB-3 23.913 0.0044
Table 3 Results for c-erbB-4 membrane accentuation
Prognostic factor c2 c2 P-value
Grade 9.935 0.0415
Lymph nodes stage 3.016 0.5552
Local recurrence 3.500 0.1738
Distant metastases 0.094 0.9543
Vascular invasion 0.785 0.6753
Tumour size 1.999 0.3681
NPI groups 10.460 0.0334
Histological type 6.345 0.3857
Age 8.900 0.3508
Menopausal status 2.166 0.3385
ER status 1.287 0.5255
EGFR 8.717 0.1901
C-erbB-2 0.761 0.6835
C-erbB-3 7.012 0.3197
Table 4 C-erbB-4 nuclear reactivity vs grade (P = 0.0291)
1 (%) 2 (%) 3 (%) Row Total
0 2 (15) 12 (24) 26 (41) 40
1 4 (31) 27 (52) 24 (38) 55
2 7 (54) 12 (24) 13 (21) 32
Column total 13 (100) 51 (100) 63 (100) 127
Table 5 C-erbB-4 cytoplasmic reactivity vs grade (P = 0.0408)
1 (%) 2 (%) 3 (%) Row total
0 0 (0) 4 (8) 7 (11) 11
1 1 (8) 22 (43) 19 (30) 42
2 9 (69) 16 (31) 32 (51) 57
3 3 (23) 9 (18) 5 (8) 17
Column total 13 (100) 51 (100) 63 (100) 127
Table 6 C-erbB-4 membrane accentuation vs grade (P = 0.0415)
1 (%) 2 (%) 3 (%) Row total
0 5 (38) 12 (24) 27 (43) 44
1 0 (0) 15 (29) 16 (25) 31
2 8 (62) 24 (47) 20 (32) 52
Column total 13 (100) 51 (100) 63 (100) 127
Table 7 C-erbB-4 membrane accentuation vs NPI (P = 0.0334)
Good prognostic (%) Average prognostic (%) Poor prognostic (%) Row
group group group Total
0 10 (34) 19 (28) 15 (50) 44
1 3 (10) 23 (34) 5 (17) 31
2 16 (55) 26 (38) 10 (33) 52
Column total 29 (100) 68 (100) 30 (100) 127c-erbB-4 protein expression in human breast cancer 1167
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Figure 1 C-erbB-4 cytoplasmic expression: the cytosol of this invasive
carcinoma shows dense immunoreactivity (´ 1600 original magnification)
Figure 3 C-erbB-4 membrane accentuation: the cellular membranes show
light but distinct reactivity in this case of low grade cribriform DCIS (´ 1600
original magnification)
Figure 5 Increasing percentage of tumour samples demonstrating score 0
cytoplasmic reactivity with increasing histological grade, and vice versa for
score 3 cytoplasmic reactivity
Figure 6 Decreasing percentage of tumour samples demonstrating score 2
membrane accentuation with increasing histological grade
Figure 4 With increasing histological grade, the percentage of tumour
samples demonstrating score 0 (absent) nuclear reactivity increases, while
that of tumours demonstrating score 2 (high) nuclear reactivity decreases
Figure 2 C-erbB-4 nuclear expression: this invasive carcinoma shows
some cytoplasmic reactivity but distinct nuclear reactivity is also visible 
(´ 1600 original magnification)
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normal tissues, including the breast. In this study, tumours with
little or no expression of c-erbB-4 tended to possess characteristics
associated with poorer prognosis in breast cancer i.e. histological
grade 3 and the NPI poor prognosis grouping (PPG). These results
suggest that an underlying mechanism of underexpression is
present, which is a significantly divergent finding. Studies on the
other members of the Type 1 family have shown repeatedly that
overexpression of the receptor is correlated with poorer prognosis
and shorter survival (Slamon et al, 1987; Lewis et al, 1990, 1996;
Klijn et al, 1992; Lemoine et al, 1992).
Srinivasan et al (1998) described a similar pattern of receptor
underexpression in their study on the expression of c-erbB-4 in
nine common human malignancies using the same monoclonal
antibody, in which they found less than normal expression of 
c-erbB-4 in 40–80% of these malignancies and in 100% of
squamous cell carcinomas of the head and neck. Another study
reported that loss of c-erbB-4 expression also occurs in prostatic
cancers as compared to benign lesions and normal prostatic tissue
(Lyne et al, 1997). However, a study on papillary thyroid
carcinomas found overexpression of c-erbB-4 in 64% of cases
(Faksvag Haugen et al, 1996). Knowlden et al (1998) examined 
c-erbB-3 and c-erbB-4 mRNA expression in human breast carci-
noma and found increased expression of both to be associated with
the prognostically favourable ER phenotype.
With regard to the other members of the Type 1 family, gene
amplification and/or an increase in gene transcription have been
shown to be responsible for protein overexpression in tumour
samples (Kageyama et al, 1988; Hollywood and Hurst, 1993). The
exact role of these receptors in the pathogenesis of breast cancer is
still being elucidated, but we can speculate that overexpression of
an oncogene encoding a putative growth factor receptor would
give a growth advantage to the cells expressing it. In the case of 
c-erbB-4, however, underexpression of the receptor seems to be
correlated with poorer clinical prognosis of breast cancer, possibly
suggesting a mechanism akin to that of tumour suppressor genes,
whereby normal suppression of mitogenesis is obliterated by loss
of function mutations.
The nuclear and cytoplasmic expression of c-erbB-4 raises
some intriguing issues, since members of the Type 1 family have
long been shown to be transmembranous glycoprotein receptors.
The cytoplasmic reactivity observed in this study may represent
the presence of the c-erbB-4 glycoprotein in the cytoplasm due to
reduced ligand-induced metabolic turnover and down-regulation
of the receptor. While binding of EGF to the EGFR rapidly
induces the clustering of ligand-receptor complexes in clathrin-
coated pits, internalization of the complexes, and finally lysosomal
degradation of both EGF and its receptor, the other Type 1
members, including c-erbB-4, are not subject to rapid internaliza-
tion and down-regulation (Baulida et al, 1996). Putative internal-
ization codes (e.g. sequences 996QQGFF and 973FYRAL) which
have been discovered within the cytoplasmic domain of EGFR are
not preserved in the cytoplasmic domain of c-erbB-4 (Chang et al,
1993). Experiments are underway to address this issue using GFP-
tagged receptors and digital microscopy.
The nuclear expression, on the other hand, is something of an
enigma, although it has been demonstrated that several of the
neuregulin isoforms do contain putative nuclear targeting
sequences near their amino termini (Holmes et al, 1992). NRG1-b
has also been reported to be internalized and efficiently trans-
ported to the nucleus in breast cancer cells (Li et al, 1996). Further
elucidation of the complex signal transduction cascades elicited by
the Type 1 receptors may explain the nuclear expression of a
receptor that at present has not been shown to be translocated to
the nucleus.
The value of a c-erbB-4 immunohistochemical assay as a
prognostic indicator in breast cancer is doubtful. As the spectrum
of expression of c-erbB-4 in this study was shown to be rela-
tively limited, semi-quantitative scoring would present difficul-
ties with inter-observer variability. Although distinguishing
between negative and positive expression may seem more easily
reproducible, our analyses demonstrate that there is no signifi-
cant correlation with patient prognosis even with this method
(data not shown). Furthermore, c-erbB-4 expression demon-
strated no significant association with either patient survival or
disease-free interval.
In conclusion, the results of this study indicate that higher levels
of c-erbB-4 protein expression are associated with a more differ-
entiated histological phenotype. Immunoreactivity with the use of
HFR-1 is generally low, although it does appear to have three
separate components: cytoplasmic (which is predominant),
nuclear and membranous. However, the immunoreactive expres-
sion of c-erbB-4 appears to be of limited prognostic value in breast
carcinoma, although it may well prove to be of greater prognostic
value in human malignancies other than the breast. Further studies
may examine this possibility as well as the role of receptor
heterodimerization in cancer progression and development.
Indeed, a recent study on childhood medulloblastoma reported that
the presence of c-erbB-4 expression with c-erbB-2 was indicative
of tumour aggressiveness and poor prognosis (Gilbertson et al,
1997). We may discover that receptor heterodimerization among
the Type 1 family of receptors plays a far more important role in
human oncogenesis than individual receptors themselves (Earp 
et al, 1995). Further studies will be enhanced by our ability to
measure all four Type 1 receptors in parallel with their known
ligands and ligand variants.
Figure 7 Decreasing percentage of tumour samples demonstrating score 2
membrane accentuation with worsening prognostic grouping. NPI,
Nottingham Prognostic Group; GPG, good prognostic group; MPG, moderate
prognostic group; PPG, poor prognostic group
Nottingham Prognostic Index grouping
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